Becton, Dickinson and Company (BDX) Covered Calls

Becton, Dickinson and Company (BD) is a global medical technology leader that manufactures and sells medical devices, instrument systems, and reagents. Headquartered in Franklin Lakes, New Jersey, the company serves healthcare institutions, life science researchers, and the pharmaceutical industry. BD focuses on improving drug delivery, enhancing the diagnosis of infectious diseases and cancer, and advancing the management of diabetes and other chronic diseases.

You can sell covered calls on Becton, Dickinson and Company to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BDX (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Becton, Dickinson and Company (BDX), commonly known as BD, is a fundamental pillar of the global healthcare supply chain. The company’s business model is centered on high-volume, essential medical consumables and sophisticated diagnostic platforms. Operating through segments like Medical Essentials and Connected Care, BD provides the foundational tools for vascular access, medication management, and surgical intervention. Its products are present in virtually every hospital worldwide, creating a massive installed base that generates consistent, recurring revenue.

By early 2026, the company has successfully executed its "New BD" strategy, highlighted by the February 2026 completion of the Biosciences and Diagnostic Solutions spin-off and merger with Waters Corporation. This multi-billion dollar transaction has sharpened the company’s focus on high-margin medical technology and "interventional" healthcare. A key pillar of the current portfolio is the Biopharma Systems unit, which provides specialized delivery systems for the majority of the world’s top biologic and GLP-1 weight-loss drugs. Despite navigating regulatory resets for its infusion platforms, BD has maintained its "Dividend Aristocrat" status, supported by robust free cash flow and a disciplined focus on operational productivity through its "BD Excellence" framework.

Competitive Landscape

The competitive landscape for BD consists of diversified healthcare conglomerates and specialized medical device manufacturers. Primary rivals that are publicly traded on the NYSE and offer highly active options markets include Medtronic plc and Baxter International Inc.. While Medtronic leads in cardiovascular and neurosurgery, Baxter is a direct competitor in the infusion pump and IV solution segments.

Other notable competitors in the medical instruments and supplies sector with active options trading include Abbott Laboratories and Boston Scientific Corporation. BD distinguishes itself through its unparalleled scale in hospital consumables; its dominance in "front-line" supplies like needles, syringes, and catheters creates a defensive moat that is difficult for peers to penetrate. This scale, combined with its leadership in Pharmacy Automation, allows BD to offer integrated "end-to-end" medication safety solutions that reduce hospital errors, a value proposition that remains highly attractive to large healthcare systems seeking efficiency and risk mitigation.

Strategic Outlook

Strategic innovation is currently centered on Smart Connected Care, where the company is integrating AI-driven insights into its medication management and patient monitoring hardware. The company is prioritizing the expansion of its Home-Based Care portfolio, developing non-invasive solutions to support the global shift toward decentralized healthcare delivery. These initiatives aim to capture higher-margin opportunities in chronic disease management while reducing reliance on traditional acute-care hospital settings.

The long-term outlook involves a commitment to "Tuck-in M&A," focusing on acquiring niche technologies that enhance its existing category leadership in vascular access and advanced tissue regeneration. Management is prioritizing a disciplined capital return policy, utilizing its strong cash flow to fund consistent dividend increases and a multi-year share repurchase authorization. By leveraging its "New BD" structure and its critical role in the biologics supply chain, Becton, Dickinson and Company aims to remain a resilient, low-volatility compounder for global investment portfolios.

Want more examples? BDTX Covered Calls | BE Covered Calls